BCX17725 — Topline data
Late 2026
On February 26, 2026, we announced that we expect to report data from the clinical trial of BCX17725 for the treatment of Netherton syndrome in up to 12 patients by the end of 2026.Source filing
BCRX biotech catalysts & pipeline
BIOCRYST PHARMACEUTICALS INC · Data as of 2026-09-08
Upcoming catalysts
navenibart — Topline data
Q3 2027
The program remains on track to report top-line results from both doses in Q3 2027.Source filing
navenibart — NDA/BLA submission
Late 2027
The program remains on track to support regulatory filing in the US by the end of 2027.Source filing